Masimo Corp

  • Health Care
  • Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • www.masimo.com
  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $8.57B
  • PE -28
  • Debt $802.50M
  • Cash $181.40M
  • EV $9.19B
  • FCF $176.40M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$304.90M
EBIT-$266.70M
ROE-29%
ROA-10%
FCF$176.40M
Equity$1.05B
Growth Stability-201%
PE-28.11
PEG1.11
PB8.15
P/FCF48.6
P/S4.09
Price/Cash0.02
Debt/Equity0.76
Debt/FCF4.55
Net Margins-15%
Gross Margins48%
Op. Margins-13%
Earnings CAGR-8%
Sales Growth YoY9%
Sales Growth QoQ19%
Sales CAGR17%
FCF CAGR-1%
Equity CAGR18%
Earnings Stability0.23
Earnings Growth YoY-1K%
Earnings Growth QoQ-4K%
Earnings CAGR 5Y-25%
Sales CAGR 5Y21%
FCF CAGR 5Y-3%
Equity CAGR 5Y-2%
Earnings CAGR 3Y13%
Sales CAGR 3Y13%
FCF CAGR 3Y-1%
Equity CAGR 3Y-3%
Market Cap$8.57B
Revenue$2.09B
Assets$2.63B
Total Debt$802.50M
Cash$181.40M
Shares Outstanding53.3M
EV9.19B
Earnings Score4%
Moat Score4%
Safety Score55%
Final Score21%
Working Capital608.1M
Current Ratio1.98
Gross Profit$1.00B
Shares Growth 3y-0%
Equity Growth QoQ-28%
Equity Growth YoY-23%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Masimo is an Irvine, California-based medical device business that focuses on noninvasive patient monitoring. It began by developing superior signal processing algorithms to measure blood oxygenation levels through pulse oximetry and has expanded this expertise into a wide range of measurements and applications. The company generates revenue globally, with the United States the largest market (67% of 2020 sales), followed by Europe, the Middle East, and Africa (21%), Asia and Australia (9%), and North and South America excluding the U.S. (3%).

SEC Filings

Direct access to Masimo Corp (MASI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 28
    • 10-Q Sep 28
    • 10-Q Jun 29
    • 10-Q Mar 30
  • 2023
    • 10-K Dec 30
    • 10-Q Sep 30
    • 10-Q Jul 01
    • 10-Q Apr 01
  • 2022
    • 10-K Dec 31
    • 10-Q Oct 01
    • 10-Q Jul 02
    • 10-Q Apr 02
    • 10-K Jan 01

Sector Comparison

How does Masimo Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Masimo Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -8%
Stability 23%
loading chart...

Masimo Corp Discounted Cash Flow

Fully customizable DCF calculator online for Masimo Corp.

= $1.6B
012345678910TV
fcf$176M$174M$171M$169M$167M$164M$162M$160M$157M$155M$153M$1.5B
DCF$158M$142M$127M$114M$102M$91M$82M$73M$66M$59M$589M
Value$1.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years01/201612/201612/201712/201812/201901/202112/202112/202212/202312/2024TTM
Net Margins13%43%16%23%21%21%19%7%4%-15%-15%
ROA-51%22%19%17%15%15%7%4%-10%-10%
ROE-54%19%20%17%17%15%11%6%-29%-29%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years01/201612/201612/201712/201812/201901/202112/202112/202212/202312/2024TTM
Debt over FCF-0----0-41.5318.774.554.55
Debt over Equity0.670----00.730.690.760.76
Growth Stability---100%94%100%100%65%40%-201%-201%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years01/201612/201612/201712/201812/201901/202112/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-10%15%8%9%22%8%64%1%2%21%
Earnings YoY growth-269%-56%47%1%22%-4%-38%-43%-474%-25%
Equity YoY growth-103%26%37%21%21%10%-14%2%-23%-2%
FCF YoY growth-522%-97%2K%-31%-10%73%-110%-314%252%-3%